Latest News

Leading New Zealand cancer research ‘super-charged’ by data privacy startup

25 May 2023, yahoo!finance

Breakfast – Trailblazing cancer drug ‘a few years away’ from clinical trials after $14m investment

Monday 12 Jul, TVNZ

$14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments

9 June 2022, LABIOTECH

Amaroq Therapeutics ‘hits early milestones’ in cancer treatment

21 June 2022 – LABIOTECH

Brandon Capital leads $14m investment to develop new cancer drug

8 July 2021, Brandon Capital

It is absolutely personal’: The determined teen who became a cancer researcher

8 July 2021, Stuff 

NZ-based startup Amaroq Therapeutics secures funding to develop cancer treatments

12 July 2021, Biospectrum Asia

Dunedin biotech startup Amaroq Therapeutics raises $14m for revolutionary ‘dark matter’ cancer treatment

7 July 2021, NZ Herald

$14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments

8 July 2021, Mirage News

Dunedin biotech company hoping to pioneer new cancer treatment

9 July 2021, 1News


Pinkney HR, Black MA, Diermeier SD. Single-cell RNA-seq reveals heterogenous lncRNA expression in xenografted triple-negative breast cancer cells. Biology 2021 Sep 30;10 (10):987 (Title Story).

Diermeier, S. D. et al. Mammary Tumor-Associated RNAs Impact Tumor Cell Proliferation, Invasion, and Migration. Cell Reports 17, 261–274 (2016).

Arun, G. et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes & Development 30, 34–51 (2016).

Diermeier, S. D. & Spector, D. L. Antisense Oligonucleotide-mediated Knockdown in Mammary Tumor Organoids. BIO-PROTOCOL 7, (2017).

Arun, G., Diermeier, S. D. & Spector, D. L. Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends Mol Med 24, 257–277 (2018).

Lucere, K. M., O’Malley, M. M. R. & Diermeier, S. D. Functional Screening Techniques to Identify Long Non-Coding RNAs as Therapeutic Targets in Cancer. Cancers 12, 3695–24 (2020).

Pinkney, H. R., Wright, B. M. & Diermeier, S. D. The lncRNA Toolkit: Databases and In Silico Tools for lncRNA Analysis. ncRNA 6, 49–25 (2020).

Chang, K.-C. et al. MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression. Nature Communications 1–19 (2020). doi:10.1038/s41467-020-20207-y

Sarkar, D. & Diermeier, S. D. Circular RNAs: Potential Applications as Therapeutic Targets and Biomarkers in Breast Cancer. ncRNA 7, 2–17 (2021).

Xiong, H., Veedu, R. N. & Diermeier, S. D. Recent Advances in Oligonucleotide Therapeutics in Oncology. IJMS 22, 3295–27 (2021).